Salinas, CA--CannaNova LLC announced in a press release its formation to pursue the consumer cannabinoid space, employing DepoFilm technology. With DepoFilm, CannaNova manufactures buccal consumer cannabinoid films.
CannaNova’s mission is to apply drug delivery principles and its second-generation oral film technology, DepoFilm, to develop and market high-performance cannabis consumables.
CannaNova CEO, Joseph Fuisz, commented in the release: “CannaNova is using DepofIlm technology to address the key challenges that consumer cannabinoid products face today. These include slow onset, low bioavailability, and inconsistent bioavailability from patient to patient. We also believe many adult consumers prefer a non-confectionery format.”
“We believe that rapid onset is particularly advantageous to allow adult consumers to enjoy consumer cannabinoids at the desired dose. Slow onset is fundamentally at odds with dose titration. Too frequently, consumers take extra edibles while mistakenly confusing slow onset for having taken too small of a dose.”
“Our hemp-derived products will be sold in eight-count child-resistant blister cards.”
CannaNova plans to launch a limited test market under its DeltaFilm brand.
Read more in the press release.